Rigel to Present at Jefferies 2018 Global Healthcare Conference

<div id="divContent"> <p>SOUTH SAN FRANCISCO, Calif., May 31, 2018 /PRNewswire/ -- <strong><a href="https://www.biospace.com/employer/248552/rigel-pharmaceuticals-inc-/">Rigel Pharmaceuticals, Inc.</a></strong> (Nasdaq: RIGL) today announced that Raul Rodriguez, the company's president and chief executive officer, is scheduled to present a company overview at the Jefferies Global Healthcare Conference in New York City on Tuesday, June 5, 2018 at 10:30am EDT.</p> <p>To access the live webcast of the presentation or the subsequent archived recording, log on to <a href="http://www.rigel.com/" rel="nofollow">www.rigel.com</a>. Please connect to Rigel's website several minutes prior to the start of the live webcast to ensure adequate time for any software download that may be necessary.</p> <p><b><u>About Rigel (<a href="http://www.rigel.com/" rel="nofollow">www.rigel.com</a>)</u></b><br /> Rigel Pharmaceuticals, Inc., is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. Rigel's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA approved product is TAVALISSEā„¢ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. Rigel's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy. In addition, Rigel has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics.</p> <p>Please see <a href="http://www.tavalisse.com/" rel="nofollow">www.TAVALISSE.com</a> for full Prescribing Information.</p> <p>Contact: Raul Rodriguez<br /> Phone: 650.624.1302<br /> Email: <a href="mailto:ir@rigel.com" rel="nofollow">ir@rigel.com</a></p> <p>Media Contact: Jessica Daitch<br /> Phone: 917.816.6712<br /> Email: <a href="mailto:jessica.daitch@syneoshealth.com" rel="nofollow">jessica.daitch@syneoshealth.com</a></p> <p>Logo - <a href="https://mma.prnewswire.com/media/681135/rigel_logo_TM_Logo.jpg" rel="nofollow">https://mma.prnewswire.com/media/681135/rigel_logo_TM_Logo.jpg</a></p> <p>&nbsp;</p> </div> <p>&nbsp; <div id="divMediaContact">&nbsp;</div> </p> <p id="PURL">View original content with multimedia:<a href="http://www.prnewswire.com/news-releases/rigel-to-present-at-jefferies-2018-global-healthcare-conference-300657013.html" id="PRNURL" rel="nofollow">http://www.prnewswire.com/news-releases/rigel-to-present-at-jefferies-2018-global-healthcare-conference-300657013.html</a></p> <p>SOURCE Rigel Pharmaceuticals, Inc.</p> <table align="center" width="100%"> <tbody> </tbody> </table>

Back to news